VectivBio Holding AG


Prices are adjusted according to historical splits.

VectivBio Holding AG Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$1.06 billion
Book Value:
Revenue TTM:
$27.34 million
Operating Margin TTM:
Gross Profit TTM:
$27.34 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

VectivBio Holding AG had its IPO on 2021-04-08 under the ticker symbol VECT.

The company operates in the Healthcare sector and Pharmaceuticals industry. VectivBio Holding AG has a staff strength of 0 employees.

Stock update

Shares of VectivBio Holding AG opened at $16.85 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $16.85 - $16.85, and closed at $16.85.

This is a 0% increase from the previous day's closing price.

A total volume of 0 shares were traded at the close of the day’s session.

In the last one week, shares of VectivBio Holding AG have increased by 0%.

VectivBio Holding AG's Key Ratios

VectivBio Holding AG has a market cap of $1.06 billion, indicating a price to book ratio of 3.6229 and a price to sales ratio of 21.079.

In the last 12-months VectivBio Holding AG’s revenue was $27.34 million with a gross profit of $27.34 million and an EBITDA of $-80416000. The EBITDA ratio measures VectivBio Holding AG's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, VectivBio Holding AG’s operating margin was -294.52% while its return on assets stood at -25.87% with a return of equity of -56.92%.

In Q1, VectivBio Holding AG’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

VectivBio Holding AG’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-2.1 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into VectivBio Holding AG’s profitability.

VectivBio Holding AG stock is trading at a EV to sales ratio of 14.3707 and a EV to EBITDA ratio of -5.2142. Its price to sales ratio in the trailing 12-months stood at 21.079.

VectivBio Holding AG stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$252.60 million
Total Liabilities
$24.74 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

VectivBio Holding AG ended 2023 with $252.60 million in total assets and $0 in total liabilities. Its intangible assets were valued at $252.60 million while shareholder equity stood at $213.37 million.

VectivBio Holding AG ended 2023 with $0 in deferred long-term liabilities, $24.74 million in other current liabilities, 3499000.00 in common stock, $-207765000.00 in retained earnings and $923000.00 in goodwill. Its cash balance stood at $221.42 million and cash and short-term investments were $221.42 million. The company’s total short-term debt was $137,000 while long-term debt stood at $0.

VectivBio Holding AG’s total current assets stands at $226.21 million while long-term investments were $0 and short-term investments were $4000.00. Its net receivables were $1.43 million compared to accounts payable of $1.80 million and inventory worth $-1434000.00.

In 2023, VectivBio Holding AG's operating cash flow was $0 while its capital expenditure stood at $42750.

Comparatively, VectivBio Holding AG paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

VectivBio Holding AG stock is currently trading at $16.85 per share. It touched a 52-week high of $16.98 and a 52-week low of $16.98. Analysts tracking the stock have a 12-month average target price of $18.

Its 50-day moving average was $15.52 and 200-day moving average was $10.14 The short ratio stood at 0.04 indicating a short percent outstanding of 0%.

Around 449.9% of the company’s stock are held by insiders while 8380.2% are held by institutions.

Frequently Asked Questions About VectivBio Holding AG

The stock symbol (also called stock or share ticker) of VectivBio Holding AG is VECT

The IPO of VectivBio Holding AG took place on 2021-04-08

Similar Industry Stocks (Pharmaceuticals)

Last Price
PAVmed Inc (PAVM)

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.


Aeschenvorstadt 36, Basel, Switzerland, 4051